In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Why the ‘last mile’ of inflation is the hardest
A year of drug decriminalization in B.C.
Fact-checking Alberta’s new gender-affirming care policies
The U.S. states vying for cheaper drugs from Canada
TD Bank’s anti-money-laundering troubles
Hells Angels, an Iranian drug lord and an alleged murder plot
The five pro hockey players charged with sexual assault
Debate around Israel-Hamas war collides with Canadian theatre
On the new frontlines of Myanmar’s civil war
What you need to know about the foreign interference inquiry
Federal Court finds Trudeau’s use of Emergencies Act unjustified
What’s driving property tax hikes in big cities?
Turning the tides into renewable energy
Invasive Group A Strep infections: what you need to know
What happens when a group of hospitals get hacked
Baby boomers mourn a future without grandkids
What’s driving Canada’s ‘population trap’?
The repercussions and fallout from the Steven Galloway case
The promise and problems with Ontario’s Ring of Fire
You’re not wrong, snowy winters aren’t like they used to be
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire